Cited by 1,709Antibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacySynthesis of β-Lactam Compounds

The DOI matches its Crossref record; 462 of the 464 references it cites were found in a registry or an index.

Three Decades of β-Lactamase Inhibitors

Open access

Drawz, Sarah M., Bonomo, Robert A.·2010·Clinical Microbiology Reviews

Open this paper in CoChat — free account

Abstract

Since the introduction of penicillin, beta-lactam antibiotics have been the antimicrobial agents of choice. Unfortunately, the efficacy of these life-saving antibiotics is significantly threatened by bacterial beta-lactamases. beta-Lactamases are now responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome beta-lactamase-mediated resistance, beta-lactamase inhibitors (clavulanate, sulbactam, and tazobactam) were introduced into clinical practice. These inhibitors greatly enhance the efficacy of their partner beta-lactams (amoxicillin, ampicillin, piperacillin, and ticarcillin) in the treatment of serious Enterobacteriaceae and penicillin-resistant staphylococcal infections. However, selective pressure from excess antibiotic use accelerated the emergence of resistance to beta-lactam-beta-lactamase inhibitor combinations. Furthermore, the prevalence of clinically relevant beta-lactamases from other classes that are resistant to inhibition is rapidly increasing. There is an urgent need for effective inhibitors that can restore the activity of beta-lactams. Here, we review the catalytic mechanisms of each beta-lactamase class. We then discuss approaches for circumventing beta-lactamase-mediated resistance, including properties and characteristics of mechanism-based inactivators. We next highlight the mechanisms of action and salient clinical and microbiological features of beta-lactamase inhibitors. We also emphasize their therapeutic applications. We close by focusing on novel compounds and the chemical features of these agents that may contribute to a "second generation" of inhibitors. The goal for the next 3 decades will be to design inhibitors that will be effective for more than a single class of beta-lactamases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/cmr.00037-09

Cites

462 of 462 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,495
Self-citation
Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,646
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,609
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,485
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,328
AmpC β-Lactamases
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,277
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,068
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,619
Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux
Nikaido, H. (1994) · Science · doi:10.1126/science.8153625 · Cited by 1,542

Show all 464 references

Research works printed but not linked: 14

Danel, F., M. G. Page, and D. M. Livermore. 2007. Class D β-lactamases, p. 163-194. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Dubus, A., P. Ledent, J. Lamotte-Brasseur, and J. M. Frere. 1996. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases. Proteins25:473-485.
Foulds, G., W. E. Barth, J. R. Bianchine, A. R. English, D. Girard, S. L. Hayes, M. O'Brien, and P. Somani. 1980. Pharmacokinetics of CP-45.899 and pro-drug CP-47.904 in animals and humans, p. 353-356. In J. D. Nelson and C. Grassi (ed.), Current chemotherapy and infectious disease. American Society for Microbiology, Washington DC.
Galleni, M., and J. M. Frere. 2007. Kinetics of β-lactamases and pencillin-binding proteins, p. 195-213. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
F1-310. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
F1-333a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Livermore, D. M., M. Akova, P. J. Wu, and Y. J. Yang. 1989. Clavulanate and β-lactamase induction. J. Antimicrob. Chemother.24(Suppl. B):23-33.
A1-006. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. 2009
Meroueh, S., J. Cha, and S. Mobashery. 2007. Inhibition of class A β-lactamases, p. 101-114. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washingtion, DC.
Page, M. G. 2007. Resistance mediated by penicllin-binding proteins, p. 81-99. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for Inhibition. ASM Press, Washington, DC.
F1-311. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
F1-0882. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Slocombe, B., A. S. Beale, R. J. Boon, K. E. Griffin, P. J. Masters, R. Sutherland, and A. R. White. 1984. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid, p. 29-49. InProgress and perspectives on β-lactamase inhibition: a review of Augmentin. Custom Communications: Postgraduate Medicine, New York, NY.

Sorted by citations

Items 301–400 of 1,001

Molecular Modeling and Simulation of the Peptidoglycan Layer of Gram-Positive Bacteria Staphylococcus aureus
Pokhrel, R., Shakya, R., Baral, P., & Chapagain, P. P. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00437 · Cited by 61
Electrochemical Biosensors for the Detection of Antibiotics in Milk: Recent Trends and Future Perspectives
Singh, B., Bhat, A., Dutta, L., Pati, K. R., Korpan, Y. I., & Dahiya, I. (2023) · Biosensors · doi:10.3390/bios13090867 · Cited by 62
Antibiotic Susceptibility of Periodontal Enterococcus faecalis
Rams, T. E., Feik, D., Mortensen, J. E., Degener, J. E., & Winkelhoff, A. J. V. (2012) · Journal of Periodontology · doi:10.1902/jop.2012.120050 · Cited by 62
A protein structure-guided covalent scaffold selectively targets the B1 and B2 subclass metallo-β-lactamases
Chen, C., Yang, X., Yang, K., Zhang, Y., Wang, W., Su, J.-P., Ge, Y., & Liu, Y. (2018) · Chemical Communications · doi:10.1039/c8cc01067f · Cited by 62
Genomic and Metagenomic Approaches for Predictive Surveillance of Emerging Pathogens and Antibiotic Resistance
Sukhum, K. V., Diorio‐Toth, L., & Dantas, G. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1535 · Cited by 60
Probing the Interaction of Aspergillomarasmine A with Metallo-β-lactamases NDM-1, VIM-2, and IMP-7
Bergström, A., Katko, A., Adkins, Z., Hill, J., Cheng, Z., Burnett, M., Yang, H., Aitha, M., Mehaffey, M. R., Brodbelt, J. S., et al. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00106 · Cited by 62
Self-citation
Living fabrication of functional semi-interpenetrating polymeric materials
Dai, Z., Yang, X., Wu, F., Wang, L., Xiang, K., Li, P., Lv, Q., Tang, J., Dohlman, A. B., Dai, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23812-7 · Cited by 61
Biochemical Characterization of CTX-M-15 from Enterobacter cloacae and Designing a Novel Non-β-Lactam-β-Lactamase Inhibitor
Faheem, M., Rehman, M. T., Danishuddin, M., & Khan, A. U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056926 · Cited by 65
N-Heterocyclic dicarboxylic acids: Broad-spectrum inhibitors of metallo-β-lactamases with co-antibacterial effect against antibiotic-resistant bacteria
Feng, L., Yang, K., Zhou, L., Xiao, J.-M., Yang, X., Zhai, L., Zhang, Y., & Crowder, M. W. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.074 · Cited by 61
Deletion of Cryptococcus neoformans AIF Ortholog Promotes Chromosome Aneuploidy and Fluconazole-Resistance in a Metacaspase-Independent Manner
Semighini, C. P., Averette, A. F., Perfect, J. R., & Heitman, J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002364 · Cited by 61
Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model
Wu, J., Racine, F., Wismer, M. K., Young, K., Carr, D. M., Xiao, J. C., Katwaru, R., Si, Q., Harradine, P. J., Motyl, M. R., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02323-17 · Cited by 61
L-lysine potentiates aminoglycosides against Acinetobacter baumannii via regulation of proton motive force and antibiotics uptake
Deng, W., Fu, T., Zhang, Z., Jiang, X. Y., Xie, J., Sun, H., Hu, P., Ren, H., Zhou, P., Liu, Q., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1740611 · Cited by 61
Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
Bhagunde, P. R., Chang, K., Hirsch, E. B., Ledesma, K. R., Nikolaou, M., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06113-11 · Cited by 60
Uncovering toxicological complexity by multi-dimensional screenings in microsegmented flow: modulation of antibiotic interference by nanoparticles
Cao, J., Kürsten, D., Schneider, S., Knauer, A., Günther, P. M., & Köhler, J. M. (2011) · Lab on a Chip · doi:10.1039/c1lc20584f · Cited by 60
Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance
Stogios, P. J., Spanogiannopoulos, P., Evdokimova, E., Egorova, O., Shakya, T., Todorovic, N., Capretta, A. A., Wright, G. D., & Savchenko, A. V. (2013) · Biochemical Journal · doi:10.1042/bj20130317 · Cited by 60
Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-β-Lactamases and Penicillin-Binding Proteins
King, A. M., King, D. T., French, S., Brouillette, É., Asli, A., Alexander, J. A. N., Vuckovic, M., Maiti, S. N., Parr, T. R., Brown, E. D., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00944 · Cited by 60
Potential therapeutic targets of Klebsiella pneumoniae: a multi-omics review perspective
Ali, S., Alam, M., Hasan, G. M., & Hassan, M. I. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab038 · Cited by 62
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals
Castanheira, M., Doyle, T. B., Deshpande, L. M., Mendes, R. E., & Sader, H. S. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106439 · Cited by 59
Lewis Base Catalyzed [4+2] Annulation of Electron‐Deficient Chromone‐Derived Heterodienes and Acetylenes
Dückert, H., Khedkar, V., Waldmann, H., & Kumar, K. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201003572 · Cited by 59
Crystal structure of L,D-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis
Li, W.-J., Li, D., Hu, Y., Zhang, X., Bi, L., & Wang, D. (2013) · Cell Research · doi:10.1038/cr.2013.53 · Cited by 59
((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies
Liu, S., Jing, L., Yu, Z., Wu, C., Zheng, Y., Zhang, E., Chen, Q., Yu, Y., Guo, L., Wu, Y., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.032 · Cited by 59
Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC
Barnes, M. D., Taracila, M. A., Good, C. E., Bajaksouzian, S., Rojas, L. J., van Duin, D., Kreiswirth, B. N., Jacobs, M. R., Haldimann, A., Papp‐Wallace, K. M., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-19 · Cited by 62
Self-citation
The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors
Gajdács, M., & Spengler, G. (2019) · Antibiotics · doi:10.3390/antibiotics8040270 · Cited by 61
The Importance of Porins and β-Lactamase in Outer Membrane Vesicles on the Hydrolysis of β-Lactam Antibiotics
Kim, S. W., Lee, J., Park, S. B., Lee, A. R., Jung, J. W., Chun, J. H., Lazarte, J. M. S., Kim, J., Seo, J., Kim, J.-H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082822 · Cited by 58
Polymicrobial biofilms related to dental implant diseases: unravelling the critical role of extracellular biofilm matrix
Costa, R. C., Bertolini, M., Oliveira, B. E. C., NAGAY, B. E., Dini, C., Benso, B., Klein, M. I., Barão, V. A. R., & Souza, J. G. S. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2062219 · Cited by 62
Factors That Affect Transfer of the IncI1 β-Lactam Resistance Plasmid pESBL-283 between E. coli Strains
Händel, N., Otte, S., Jonker, M. J., Brul, S., & ter Kuile, B. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123039 · Cited by 58
Insights into β-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants
Papp‐Wallace, K. M., Taracila, M. A., Gatta, J. A., Ohuchi, N., Bonomo, R. A., & Nukaga, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.458315 · Cited by 58
Self-citation
Applying ecological resistance and resilience to dissect bacterial antibiotic responses
Meredith, H. R., Andreani, V., Ma, H. R., Lopatkin, A. J., Lee, A. J., Anderson, D. J., Batt, G., & You, L. (2018) · Science Advances · doi:10.1126/sciadv.aau1873 · Cited by 56
Structures of the Michaelis Complex (1.2 Å) and the Covalent Acyl Intermediate (2.0 Å) of Cefamandole Bound in the Active Sites of the Mycobacterium tuberculosis β-Lactamase K73A and E166A Mutants,
Tremblay, L. W., Xu, H., & Blanchard, J. S. (2010) · Biochemistry · doi:10.1021/bi1015088 · Cited by 58
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Du, S., Hu, X., Menéndez‐Arias, L., Zhan, P., & Liu, X. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101053 · Cited by 61
Genome-Wide Identification of Antimicrobial Intrinsic Resistance Determinants in Staphylococcus aureus
Vestergaard, M. R., Leng, B., Haaber, J., Bojer, M. S., Vegge, C. S., & Ingmer, H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02018 · Cited by 58
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate
Thambavita, D., Galappatthy, P., Mannapperuma, U., Jayakody, L., Cristofoletti, R., Abrahamsson, B., Groot, D. W., Langguth, P., Mehta, M., Parr, A. F., et al. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.068 · Cited by 57
Multiwall Carbon Nanotubes Induce More Pronounced Transcriptomic Responses in Pseudomonas aeruginosa PG201 than Graphene, Exfoliated Boron Nitride, or Carbon Black
Mortimer, M., Devarajan, N., Li, D., & Holden, P. A. (2018) · ACS Nano · doi:10.1021/acsnano.7b08977 · Cited by 57
Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1
Jin, W., Xu, C., Cheng, Q., Qi, X. L., Gao, W., Zheng, Z., Chan, E. W., Leung, Y., Chan, T. H., Wong, K., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.007 · Cited by 57
Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018
Gaibani, P., Lombardo, D., Bussini, L., Bovo, F., Munari, B., Giannella, M., Bartoletti, M., Viale, P., Lazzarotto, T., & Ambretti, S. (2021) · Antibiotics · doi:10.3390/antibiotics10050536 · Cited by 57
Structure-activity relationship study and optimisation of 2-aminopyrrole-1-benzyl-4,5-diphenyl-1 H -pyrrole-3-carbonitrile as a broad spectrum metallo-β-lactamase inhibitor
McGeary, R. P., Tan, D. T. C., Selleck, C., Pedroso, M. M., Sidjabat, H. E., & Schenk, G. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.061 · Cited by 56
Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance
Shi, K., Caldwell, S. J., Fong, D. H., & Berghuis, A. M. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00022 · Cited by 56
Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate
Soroka, D., Ourghanlian, C., Compain, F., Fichini, M., Dubée, V., Mainardi, J., Hugonnet, J., & Arthur, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw546 · Cited by 55
Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam
Slater, C., Winogrodzki, J. L., Fraile-Ribot, P. A., Oliver, A., Khajehpour, M., & Mark, B. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00894-20 · Cited by 55
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination
Mansour, H., Ouweini, A. E., Chahine, E. B., & Karaoui, L. R. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab012 · Cited by 55
Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design
Rojas, L. J., Taracila, M. A., Papp‐Wallace, K. M., Bethel, C. R., Caselli, E., Romagnoli, C., Winkler, M., Spellberg, B. J., Prati, F., & Bonomo, R. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02641-15 · Cited by 54
Self-citation
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens
Vrâncianu, C. O., Gheorghe, I., Dobre, E.-G., Barbu, I. C., Cristian, R.-E., Popa, M., Lee, S. H., Limban, C., Vlad, I. M., & Chifiriuc, M. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228527 · Cited by 55
New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics
Σαργιάνου, Μ., Stathopoulos, P., Vrysis, C., Tzvetanova, I. D., & Falagas, M. E. (2025) · Pathogens · doi:10.3390/pathogens14040307 · Cited by 54
The synthesis and antibacterial activity of pyrazole-fused tricyclic diterpene derivatives
Yu, L., Ni, T., Gao, W., He, Y., Wang, Y., Cui, H., Yang, C., & Qiu, W. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.015 · Cited by 54
Mistranslation drives the evolution of robustness in TEM-1 β-lactamase
Bratulić, S., Gerber, F., & Wagner, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510071112 · Cited by 54
In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48–positive Klebsiella pneumoniae strains
Evren, E., Azap, Ö. K., Çolakoğlu, Ş., & Arslan, H. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.04.004 · Cited by 54
Azolylthioacetamide: A Highly Promising Scaffold for the Development of Metallo-β-lactamase Inhibitors
Yang, S.-K., Kang, J. S., Oelschlaeger, P., & Yang, K. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500534c · Cited by 54
blaCTX-M-152, a Novel Variant of CTX-M-group-25, Identified in a Study Performed on the Prevalence of Multidrug Resistance among Natural Inhabitants of River Yamuna, India
Azam, M., Jan, A. T., & Haq, Q. M. R. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00176 · Cited by 54
A Self‐Immobilizing and Fluorogenic Probe for β‐Lactamase Detection
Mao, W., Xia, L., Wang, Y., & Xie, H. (2016) · Chemistry - An Asian Journal · doi:10.1002/asia.201601344 · Cited by 54
Reconciling the Potentially Irreconcilable? Genotypic and Phenotypic Amoxicillin-Clavulanate Resistance in Escherichia coli
Davies, T. J., Stoesser, N. E., Sheppard, A. E., AbuOun, M., Fowler, P. W., Swann, J., Quan, T. P., Griffiths, D., Vaughan, A., Morgan, M. R., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02026-19 · Cited by 54
Self-citation
Modular, stereocontrolled C β –H/C α –C activation of alkyl carboxylic acids
Shang, M., Feu, K. S., Vantourout, J. C., Barton, L. M., Osswald, H. L., Kato, N., Gagaring, K., McNamara, C. W., Chen, G., Hu, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903048116 · Cited by 53
Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells
Magkoufopoulou, C., Claessen, S. M. H., Jennen, D. G. J., Kleinjans, J. C. S., & van Delft, J. H. M. (2011) · Mutagenesis · doi:10.1093/mutage/ger021 · Cited by 55
The Role of the Ω-Loop in Regulation of the Catalytic Activity of TEM-Type β-Lactamases
Egorov, A. M., Rubtsova, M. Y., Григоренко, В. Г., Uporov, I. V., & Veselovsky, A. V. (2019) · Biomolecules · doi:10.3390/biom9120854 · Cited by 54
A Natural Dietary Flavone Myricetin as an α-Hemolysin Inhibitor for Controlling Staphylococcus aureus Infection
Wang, T., Zhang, P., Lv, H., Deng, X., & Wang, J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00330 · Cited by 53
The return of Pfeiffer’s bacillus: Rising incidence of ampicillin resistance in Haemophilus influenzae
Heinz, E. (2018) · Microbial Genomics · doi:10.1099/mgen.0.000214 · Cited by 52
A novel flow cytometric assay for rapid detection of extended-spectrum beta-lactamases
Faria‐Ramos, I., Espinar, M. J., Rocha, R., Santos‐Antunes, J., Rodrigues, A. G., Cantón, R., & Pina‐Vaz, C. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03986.x · Cited by 52
Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276
Papp‐Wallace, K. M., Taracila, M. A., Smith, K. M., Xu, Y., & Bonomo, R. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05769-11 · Cited by 52
Self-citation
Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
Felton, T., McCalman, K., Malagon, I. L., Isalska, B. J., Whalley, S., Goodwin, J., Bentley, A. M., & Hope, W. W. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.131 · Cited by 52
Crystal Structures of KPC-2 β-Lactamase in Complex with 3-Nitrophenyl Boronic Acid and the Penam Sulfone PSR-3-226
Ke, W., Bethel, C. R., Papp‐Wallace, K. M., Pagadala, S. R. R., Nottingham, M., Fernández, D., Buynak, J. D., Bonomo, R. A., & van den Akker, F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06099-11 · Cited by 52
Self-citation
The global need for effective antibiotics—A summary of plenary presentations
Alván, G., Edlund, C., & Heddini, A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.007 · Cited by 52
Synthesis and biological evaluation of Aspergillomarasmine A derivatives as novel NDM-1 inhibitor to overcome antibiotics resistance
Zhang, J., Wang, S., Wei, Q., Guo, Q., Bai, Y., Yang, S., Song, F., Zhang, L., & Lei, X. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.025 · Cited by 52
Management of infections caused by extended-spectrum β–lactamase-producing Enterobacteriaceae : current evidence and future prospects
Sheu, C., Lin, S., Chang, Y.-T., Lee, C.-Y., Chen, Y., & Hsueh, P. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1436966 · Cited by 53
A simple design of fluorescent probes for indirect detection of β-lactamase based on AIE and ESIPT processes
Peng, L., Xiao, L., Ding, Y., Xiang, Y., & Tong, A. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00414e · Cited by 52
Resveratrol enhances the efficacy of aminoglycosides against Staphylococcus aureus
Nøhr-Meldgaard, K., Ovsepian, A., Ingmer, H., & Vestergaard, M. R. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.06.005 · Cited by 55
In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae
Moyá, B., Barceló, I. M., Cabot, G., Torrens, G., Palwe, S. R., Joshi, P., Umarkar, K., Takalkar, S., Periasamy, H., Bhagwat, S., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00128-19 · Cited by 52
Antibiotic Resistance and the MRSA Problem
Vestergaard, M. R., Frees, D., & Ingmer, H. (2019) · ASM Press eBooks · doi:10.1128/9781683670131.ch47 · Cited by 53
β-Lactamase Inhibitors: An Update
Chen, J., Shang, X., Hu, F., Lao, X., Gao, X., Zheng, H., & Yao, W. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113139990074 · Cited by 51
Total Synthesis and Structural Reassignment of Aspergillomarasmine A
Liao, D., Yang, S., Wang, J., Zhang, J., Hong, B., Wu, F., & Lei, X. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201509960 · Cited by 51
In vitro evaluation of metal chelators as potential metallo- β -lactamase inhibitors
Azumah, R., Dutta, J., Somboro, A. M., Ramtahal, M. A., Chonco, L., Parboosing, R., Bester, L. A., Kruger, H. G., Naicker, T., Essack, S. Y., et al. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13085 · Cited by 51
Orally Absorbed Derivatives of the β-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs
Gordon, E. M., Duncton, M. A. J., & Gallop, M. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01389 · Cited by 51
A systematic review and meta-analysis of antimicrobial resistance in paediatric acute otitis media
Mather, M. W., Drinnan, M. J., Perry, J. D., Powell, S. M., Wilson, J. A., & Powell, J. (2019) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2019.04.041 · Cited by 51
Comparative Biochemical and Computational Study of the Role of Naturally Occurring Mutations at Ambler Positions 104 and 170 in GES β-Lactamases
Kotsakis, S. D., Miriagou, V., Tzelepi, Ε., & TZOUVELEKIS, L. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00771-10 · Cited by 51
Crystal structures of VIM‐1 complexes explain active site heterogeneity in VIM‐class metallo‐β‐lactamases
Salimraj, R., Hinchliffe, P., Kosmopoulou, M. N., Tyrrell, J. M., Brem, J., van Berkel, S. S., Verma, A. K., Owens, R. J., McDonough, M. A., Walsh, T. R., et al. (2018) · FEBS Journal · doi:10.1111/febs.14695 · Cited by 50
Reappraising the use of β-lactams to treat tuberculosis
Kurz, S. G., & Bonomo, R. A. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.96 · Cited by 50
Self-citation
Targeting Class A and C Serine β-Lactamases with a Broad-Spectrum Boronic Acid Derivative
Tondi, D., Venturelli, A., Bonnet, R., Pozzi, C., Shoichet, B. K., & Costi, M. P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006572 · Cited by 50
Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-β-lactamases
Mojica, M. F., Mahler, G., Bethel, C. R., Taracila, M. A., Kosmopoulou, M. N., Papp‐Wallace, K. M., Llarrull, L. I., Wilson, B. M., Marshall, S. H., Wallace, C. J., et al. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00106 · Cited by 50
Self-citation
What Approaches to Thwart Bacterial Efflux Pumps-Mediated Resistance?
Seukep, A. J., Mbuntcha, H. G., Kuete, V., Chu, Y., Fan, E., & Guo, M. (2022) · Antibiotics · doi:10.3390/antibiotics11101287 · Cited by 50
In Vitro and In Vivo Properties of BAL30376, a β-Lactam and Dual β-Lactamase Inhibitor Combination with Enhanced Activity against Gram-Negative Bacilli That Express Multiple β-Lactamases
Page, M. G. P., Dantier, C., Desarbre, E., Gaucher, B., Gebhardt, K., & Schmitt‐Hoffmann, A. H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01370-10 · Cited by 49
Exploring sequence requirements for C3/C4 carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β‐lactamase
Drawz, S. M., Taracila, M. A., Caselli, E., Prati, F., & Bonomo, R. A. (2011) · Protein Science · doi:10.1002/pro.612 · Cited by 49
Self-citation
The development of efflux pump inhibitors to treat Gram-negative infections
Blanco, P., Sanz‐García, F., Hernando‐Amado, S., Martínez, J. L., & Alcalde‐Rico, M. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1514386 · Cited by 49
Inactivating pathogenic bacteria in greywater by biosynthesized Cu/Zn nanoparticles from secondary metabolite of Aspergillus iizukae; optimization, mechanism and techno economic analysis
Noman, E. A., Al-Gheethi, A. A. S., Talip, B. A., Mohamed, R. M. S. R., & Kassim, A. H. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221522 · Cited by 50
Identifying Oxacillinase-48 Carbapenemase Inhibitors Using DNA-Encoded Chemical Libraries
Taylor, D. M., Anglin, J. L., Park, S., Ucisik, M. N., Faver, J. C., Simmons, N., Jin, Z., Palaniappan, M., Nyshadham, P., Li, F., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00015 · Cited by 49
A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
Campanella, T. A., & Gallagher, J. C. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s224228 · Cited by 48
Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding
Hirvonen, V. H. A., SPENCER, J. M., & van der Kamp, M. W. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00184-21 · Cited by 48
Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii
Kuo, S., Lee, Y., Lauderdale, T.-L. Y., Huang, W., Chuang, M.-F., Chen, C.-P., Su, S.-C., Lee, K., & Chen, T.-L. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00231 · Cited by 48
β-Lactam Antibiotics Renaissance
Qin, W., Panunzio, M., & Biondi, S. (2014) · Antibiotics · doi:10.3390/antibiotics3020193 · Cited by 49
Molecular Mechanisms of Substrate Recognition and Specificity of New Delhi Metallo-β-Lactamase
Chiou, J. A., Leung, T. Y.-C., & Chen, S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01977-13 · Cited by 48
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates
Zhang, D., Wang, Y., Lu, J. L., & Pang, Y. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01035-15 · Cited by 48
Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants
Djoko, K. Y., Achard, M. E. S., Phan, M., Lo, A. W. H., Miraula, M., Prombhul, S., Hancock, S. J., Peters, K. M., Sidjabat, H. E., Harris, P. N. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02280-17 · Cited by 48
2D-MoS2-Based β-Lactamase Inhibitor for Combination Therapy against Drug-Resistant Bacteria
Ali, S. R., Pandit, S., & De, M. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00105 · Cited by 48
Ultraporous Polyquaternium-Carboxylated Chitosan Composite Hydrogel Spheres with Anticoagulant, Antibacterial, and Rapid Endotoxin Removal Profiles for Sepsis Treatment
Liu, X., Xu, T., Jiang, C., Li, Y., Su, B., Zhao, W., & Zhao, C. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00583 · Cited by 48
Solar photocatalytic oxidation of recalcitrant natural metabolic by-products of amoxicillin biodegradation
Pereira, J. H. O. S., Reis, A. C., Homem, V., Silva, J. A., Alves, A., Borges, M.-T., Boaventura, R. A. R., Vilar, V. J. P., & Nunes, O. C. (2014) · Water Research · doi:10.1016/j.watres.2014.07.037 · Cited by 47
Design, synthesis, and in vitro and biological evaluation of potent amino acid-derived thiol inhibitors of the metallo-β-lactamase IMP-1
Arjomandi, O. K., Hussein, W. M., Vella, P., Yusof, Y., Sidjabat, H. E., Schenk, G., & McGeary, R. P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.017 · Cited by 47
Antibacterial Properties of Metallocenyl-7-ADCA Derivatives and Structure in Complex with CTX-M β-Lactamase
Lewandowski, E. M., Szczupak, Ł., Wong, S., Skiba, J., Guśpiel, A., Solecka, J., Vrček, V., Kowalski, K., & Chen, Y. (2017) · Organometallics · doi:10.1021/acs.organomet.6b00888 · Cited by 47
Structural/mechanistic insights into the efficacy of nonclassical β‐lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates
Calvopiña, K., Hinchliffe, P., Brem, J., Heesom, K. J., Johnson, S., Cain, R. M., Lohans, C. T., Fishwick, C. W. G., Schofield, C. J., SPENCER, J. M., et al. (2017) · Molecular Microbiology · doi:10.1111/mmi.13831 · Cited by 47
Spatial Structure of the Mormon Cricket Gut Microbiome and its Predicted Contribution to Nutrition and Immune Function
Smith, C. C., Srygley, R. B., Healy, F. G., Swaminath, K., & Mueller, U. G. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00801 · Cited by 46
Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin–cyclam conjugates
Idowu, T., Ammeter, D., Arthur, G., Zhanel, G. G., & Schweizer, F. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz228 · Cited by 47
Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) β-Lactamase
Winkler, M., Rodkey, E. A., Taracila, M. A., Drawz, S. M., Bethel, C. R., Papp‐Wallace, K. M., Smith, K. M., Xu, Y., Dwulit‐Smith, J. R., Romagnoli, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301490d · Cited by 45
Self-citation
Structural and Kinetic Studies on Metallo-β-lactamase IMP-1
Griffin, D. H., Richmond, T. K., Sanchez, C., Moller, A., Breece, R. M., Tierney, D. L., Bennett, B., & Crowder, M. W. (2011) · Biochemistry · doi:10.1021/bi200839h · Cited by 45
Systematic Analysis of Metallo-β-Lactamases Using an Automated Database
Widmann, M., Pleiss, J., & Oelschlaeger, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00255-12 · Cited by 45

Authors: Drawz, S. M., & Bonomo, R. A.
Affiliations: Departments of Pathology
United States Department of Veterans Affairs (US)
Corresponding author: Bonomo, Robert A.
ORCID: Bonomo, Robert A.
Venue: Clinical Microbiology Reviews
Publisher: American Society for Microbiology
Published: 2010-01
Volume: 23
Issue: 1
Pages: 160-201
ISSN: 0893-8512 (ISSN-L)
1098-6618
DOI: 10.1128/cmr.00037-09
PMC: PMC2806661
OpenAlex: W1895007034
Cited by: 1,709
References: 464
Citations by year: 2026: 83 · 2025: 100 · 2024: 87 · 2023: 86 · 2022: 106 · 2021: 126 · 2020: 151 · 2019: 130 · 2018: 131 · 2017: 119 · 2016: 120 · 2015: 108 · 2014: 93 · 2013: 88 · 2012: 81
FWCI: 4.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Clinical Microbiology Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Public Health Service (1R01A1063517-01)
National Institute of General Medical Sciences (T32GM007250, T32GM07250)
Topics: Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Physical Sciences › Chemistry › Organic Chemistry › Synthesis of β-Lactam Compounds
Keywords: beta-lactamase inhibitors, beta-lactamase, beta-lactam resistance, clavulanic acid, sulbactam, tazobactam, mechanism-based inactivators, carbapenemase inhibitors, extended-spectrum cephalosporin resistance, Enterobacteriaceae, penicillin-resistant staphylococci
MeSH terms: Bacteria, Bacterial Infections, Bacterial Proteins, beta-Lactamases, Enzyme Inhibitors, Humans, beta-Lactam Resistance, beta-Lactamase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Three Decades of β-Lactamase Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks